Nyxoah's mission is to become a world-leading company by offering unique, patient-centric neuromodulation solutions, developed by passionate and exceptionally-driven people. Nyxoah’s lead solution platform is based on the Genio® system, a CE-Mark validated, patient-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the world’s most common sleep disordered breathing condition that is associated with increased mortality risk* and comorbidities including cardiovascular diseases, depression and stroke.
At-a-Glance
Genio is an alternative treatment for all those who can't tolerate CPAP therapy
Genio uses hypoglossal nerve stimulation (HGNS) to prevent the tongue from falling back and blocking the upper airway while patients sleep
The effectiveness of this therapy has been scientifically proven in patients with moderate to severe obstructive sleep apnea
